Amylyx Pharmaceuticals (AMLX) Change in Receivables (2022 - 2025)
Amylyx Pharmaceuticals (AMLX) posted quarterly Change in Receivables of -$44000.0 for Q4 2025, up 96.57% year-over-year from -$22383.8 in Q4 2024, and down 246.67% quarter-over-quarter from $30000.0 in Q3 2025.
Amylyx Pharmaceuticals (AMLX) Change in Receivables (2022 - 2025) Analysis & Trends
Amylyx Pharmaceuticals' Change in Receivables history runs 4 years deep, the most recent figure standing at -$44000.0 for Q4 2025.
- In Q4 2025, Change in Receivables rose 96.57% year-over-year to -$44000.0; the TTM figure through Dec 2025 stood at -$359000.0 (up 99.09% YoY), while the FY2025 annual figure was -$359000.0, up 99.09% from the prior year.
- Change in Receivables for Q4 2025 stood at -$44000.0, down from $30000.0 in the prior quarter.
- The five-year high for Change in Receivables was $15.9 million in Q2 2023, with the low at -$19.7 million in Q1 2024.
- The 4-year median for Change in Receivables is -$147000.0 (2025), against an average of -$3692.3.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables slumped 975.86% in 2024, then soared 101.27% in 2025.
- Amylyx Pharmaceuticals' Change in Receivables stood at $15.2 million in 2022, then retreated by 29.48% to $10.7 million in 2023, then slumped by 111.99% to -$1.3 million in 2024, then jumped by 96.57% to -$44000.0 in 2025.
- Business Quant data shows AMLX's Change in Receivables at -$44000.0 in Q4 2025, $30000.0 in Q3 2025, and -$198000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -44,000.00 |
| Dec 31, 2025 | -44,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | -198,000.00 |
| Jun 30, 2025 | -198,000.00 |
| Mar 31, 2025 | -147,000.00 |
| Mar 31, 2025 | -147,000.00 |
| Dec 31, 2024 | -1.28 Mn |
| Dec 31, 2024 | -1.28 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -16.26 Mn |
| Jun 30, 2024 | -16.26 Mn |
| Mar 31, 2024 | -19.70 Mn |
| Mar 31, 2024 | -19.70 Mn |
| Dec 31, 2023 | 10.70 Mn |
| Dec 31, 2023 | 10.70 Mn |
| Sep 30, 2023 | -4.12 Mn |
| Sep 30, 2023 | -4.12 Mn |